New distribution agreement

RNS Number : 1343V
Timestrip PLC
06 July 2009

Timestrip plc

('Timestrip' or the 'Company')

New distribution agreement

The Company is delighted to announce further progress with its commercialization of TimestripIV, the innovative technology that enables clinicians and patients to quickly assess how long a cannula has been in place and thus take appropriate action in line with hospital infection control procedures. 

The Company has appointed Vygon (UK) Limited as the Main Distributor for TimestripIV products in the United Kingdom and Ireland. Vygon (UK) Ltd is a leading supplier of single-use medical and surgical products, including intravenous access devices, to the NHS. Vygon (UK) Ltd is part of The Vygon Group of Companies which have supplied the healthcare profession for over 40 years.

TimestripIV will be available to hospitals through the NHS Supply Chain from the end of July. Vygon also intends to include TimestripIV as a component in a new cannulation pack that will be available in the coming months. In addition, Vygon will act as the reseller of TimestripIV to other manufacturers of intravenous access devices and cannulation packs, thereby ensuring the widest possible availability for the product to the NHS and private hospital groups.

Paul Freedman, Joint CEO, Timestrip Plc: 'We are delighted to be partnering with such a dynamic and professional company as Vygon. They have a significant reach into the NHS supply chain and have an outstanding approach to introducing new products to the healthcare market. Their agreement to commit significant resources to the launch of TimestripIV means that it will have the best possible chance of success.'

Les Davies, Managing Director, Vygon UK: 'We have been very impressed by the innovative nature of this product and the positive feedback it has received both in pilot studies and also from a wider audience of stakeholders in the NHS. TimestripIV is a natural fit with our extensive range of intravenous devices. Current statistics reveal that in the UK alone there are over 40 million venepuncture and cannulation procedures a year and we are confident that our proven strength in this market will help the product to achieve its considerable potential.'


For further information:

Paul Freedman, Joint CEO, Timestrip                01462-440700

Geoff Nash/Ed Frisby, Finncap                             0207 600 1658

This information is provided by RNS
The company news service from the London Stock Exchange
UK 100

Latest directors dealings